Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Revisiting Immunotherapy: A Focus on Prostate Cancer
Ha-Ram Cha, Joo Hyoung Lee, Selvarangan Ponnazhagan
Cancer Research (2020) Vol. 80, Iss. 8, pp. 1615-1623
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Hormonal Therapy for Prostate Cancer
Kunal Desai, Jeffrey M. McManus, Nima Sharifi
Endocrine Reviews (2021) Vol. 42, Iss. 3, pp. 354-373
Open Access | Times Cited: 269
Inflammation-Induced Tumorigenesis and Metastasis
Sana Hibino, Tetsuro Kawazoe, Hidenori Kasahara, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5421-5421
Open Access | Times Cited: 170
Therapeutic targeting of tumour myeloid cells
Simon T. Barry, Dmitry I. Gabrilovich, Owen J. Sansom, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 4, pp. 216-237
Closed Access | Times Cited: 149
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance
Rongbin Ge, Zongwei Wang, Liang Cheng
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 91
A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy
He Wang, Zhiyuan Gao, Di Jiao, et al.
Advanced Functional Materials (2023) Vol. 33, Iss. 16
Closed Access | Times Cited: 51
The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy
Dechao Feng, Weizhen Zhu, Jie Wang, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Extracellular Vesicles from Akkermansia muciniphila Elicit Antitumor Immunity Against Prostate Cancer via Modulation of CD8+ T Cells and Macrophages
Zhong‐Wei Luo, Kun Xia, Yi-Wei Liu, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 2949-2963
Open Access | Times Cited: 100
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Dhruv Bansal, Melissa A. Reimers, E Knoche, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 334-334
Open Access | Times Cited: 61
Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors
Matteo Gallazzi, Denisa Baci, Lorenzo Mortara, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 58
Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer
Guopeng Yu, Jia-hao Bao, Ming Zhan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer
Abdulmottaleb E. Zetrini, HoYin Lip, Azhar Z. Abbasi, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 35
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies
Wei Shi, Yin Wang, Yuehui Zhao, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 695
Open Access | Times Cited: 31
Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy
Xianyanling Yi, Jin Li, Xiaonan Zheng, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 33, pp. 376-390
Open Access | Times Cited: 30
Progression in immunotherapy for advanced prostate cancer
Hao Liang, Yang Liu, Jiao Guo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 27
Prostate cancer grading framework based on deep transfer learning and Aquila optimizer
Hossam Magdy Balaha, Ahmed Osama Shaban, Eman M. El-Gendy, et al.
Neural Computing and Applications (2024) Vol. 36, Iss. 14, pp. 7877-7902
Open Access | Times Cited: 15
Causal relationship between immune cells and prostate cancer: a Mendelian randomization study
Zhipeng Ye, Xinpei Deng, Jinhui Zhang, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 14
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
Nicholas A. Zorko, Allison Makovec, Andrew Elliott, et al.
Prostate Cancer and Prostatic Diseases (2024)
Open Access | Times Cited: 9
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3200-3210
Closed Access | Times Cited: 8
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Sujit S. Nair, Rachel Weil, Zachary Dovey, et al.
Urologic Clinics of North America (2020) Vol. 47, Iss. 4, pp. e17-e54
Open Access | Times Cited: 65
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Kevin Dang, Giulia Castello, Starlynn Clarke, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002488-e002488
Open Access | Times Cited: 41
PEGylated Manganese–Zinc Ferrite Nanocrystals Combined with Intratumoral Implantation of Micromagnets Enabled Synergetic Prostate Cancer Therapy via Ferroptotic and Immunogenic Cell Death
Hui Wang, Yu Guan, Chun Li, et al.
Small (2023) Vol. 19, Iss. 22
Closed Access | Times Cited: 21
Circulating and Tumor-Associated Neutrophils in the Era of Immune Checkpoint Inhibitors: Dynamics, Phenotypes, Metabolism, and Functions
Lara Gibellini, Rebecca Borella, Elena Santacroce, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3327-3327
Open Access | Times Cited: 16
Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research
Mohammad Waseem, Bi‐Dar Wang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1093-1093
Open Access | Times Cited: 7
The potential of CAR T cell therapy for prostate cancer
Philipp Wolf, Jamal Alzubi, Christian Gratzke, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 9, pp. 556-571
Closed Access | Times Cited: 35
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer
Masayuki Hagiwara, Atsushi Fushimi, Atrayee Bhattacharya, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top